BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Last update: yesterday, 10:21PM54.26
0.45 (0.84%)
| Previous Close | 53.81 |
| Open | 54.71 |
| Volume | 1,491,489 |
| Avg. Volume (3M) | 2,379,617 |
| Market Cap | 10,372,803,584 |
| Price / Sales | 42.85 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Viking Global Investors Lp | 30 Jun 2025 | 18,555,375 |
| Kohlberg Kravis Roberts & Co. L.P. | 30 Jun 2025 | 13,260,971 |
| Aisling Capital Management Lp | 30 Jun 2025 | 6,068,125 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 75.08%) | Buy |
| Median | 70.00 (29.01%) | |
| Low | 57.00 (Scotiabank, 5.05%) | Buy |
| Average | 70.57 (30.06%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 49.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 21 Oct 2025 | 59.00 (8.74%) | Buy | 54.36 |
| HC Wainwright & Co. | 15 Sep 2025 | 70.00 (29.01%) | Buy | 51.47 |
| 03 Sep 2025 | 70.00 (29.01%) | Buy | 51.84 | |
| UBS | 12 Sep 2025 | 82.00 (51.12%) | Buy | 51.21 |
| JP Morgan | 03 Sep 2025 | 70.00 (29.01%) | Buy | 51.84 |
| Oppenheimer | 06 Aug 2025 | 61.00 (12.42%) | Buy | 44.81 |
| Scotiabank | 06 Aug 2025 | 57.00 (5.05%) | Buy | 44.81 |
| Cantor Fitzgerald | 29 Jul 2025 | 95.00 (75.08%) | Buy | 46.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |